Head and Neck CancerNCT06152055
Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal
An observational study of Head and Neck Cancer, run by Tribhuvan University, Nepal at 1 site in Nepal.
Trial summary
This is a observational study conducted at the department of Ear ,Nose and Throat -Head and Neck Surgery (ENT-HNS) of Shree Birendra Hospital ,a tertiary health care centre of Nepal. Head and Neck cancers are the sixth most common cancer in the world. Read more about this study
- Who is it for?
- Ages 17 to 84 years
- Conditions the study is for
- Head and Neck Cancer
- How many people
- 76 participants
- Where
- 1 siteNepal
- Study dates
- 1 May 2022to 30 Apr 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 84 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Study population was selected from the tertiary care centre of Nepal.
Who may be able to join
- All histologically proven cases of head and neck region.
Who cannot join
- Patient's record with incomplete data.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal - A Retrospective Study
This is a observational study conducted at the department of Ear ,Nose and Throat -Head and Neck Surgery (ENT-HNS) of Shree Birendra Hospital ,a tertiary health care centre of Nepal. Head and Neck cancers are the sixth most common cancer in the world. Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023.The main aim of the study was to know about the common cancers of head and neck region and their distribution according to the site. Also to know the stage of the presentation with treatment modalities in the tertiary health care centre of Nepal.
Read the detailed description
This is a retrospective study to know the prevalence of Head and Neck Cancer at the department of ENT- Head and Neck Surgery of Shree Birendra Hospital ,a tertiary health care centre of Nepal .Head and neck cancers are malignant neoplasms that develops in oral cavity, nasal cavities, paranasal sinuses,nasopharynx, oropharynx, hypopharynx, ear, scalp, salivary gland and neck,Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023. Data considered of demographic details of age, sex, diagnosis, subsite specific Head and Neck Cancers, treatment modality and histopathology. The data was analyzed using Stastical Package for Social Sciences (SPSS) version 22. Pearson's chi-square test was applied and p value <0.05 was considered statistically significant.
- Conditions
- Head and Neck Cancer
- Keywords
- Head and Neck Cancer, Radiotherapy, Chemotherapy
- Medical subject headings
- Head and Neck Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Age - wise Distribution of Head and Neck Cancers (HNCs)
Age - wise Distribution of Head and Neck Cancer
Measured: 1 year
: Distribution of HNCs according to subsite
Distribution of Head and Neck Cancers according to the subsite
Measured: 1 year
Histopathology of HNCs
Histopathology of Head and Neck Cancer
Measured: 1 year
Tumor, Nodes, Metastasis (TNM) staging of HNC
Staging at presentation of Head and Neck Cancer
Measured: 1 year
Treatment provided to HNC patients
Treatment Modalities of Head and Neck Cancer
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2023
- Study start1 May 2022
- Primary completion30 Apr 2023
- Study completion30 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Head and Neck CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 76 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tribhuvan University, Nepal
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Anupama Marasini, Tribhuvan University, Nepal
- Investigators
- Reeba Karki, MS, Principal investigator, Shree Birendra Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06152055
- Sponsor's protocol ID
- 245
- Status last verified
- Nov 2023
- First submitted
- 21 Nov 2023
- Last updated
- 30 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to share the individual participant data to protect the privacy of the participants.
Publications
Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8. doi: 10.1586/14737140.6.7.1111.
PubMed 16831082
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal - A Retrospective Study
- ClinicalTrials.gov ID
- NCT06152055
- Acronym / sponsor ID
- 245
- Conditions
- Head and Neck Cancer
- Keywords
- Head and Neck Cancer, Radiotherapy, Chemotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 76 participants (actual)
- Lead sponsor
- Tribhuvan University, NepalUniversity, hospital or other
- Study start
- 1 May 2022 (actual)
- Primary completion
- 30 Apr 2023 (actual)
- Study completion
- 30 Apr 2023 (actual)
- First posted
- 30 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a observational study conducted at the department of Ear ,Nose and Throat -Head and Neck Surgery (ENT-HNS) of Shree Birendra Hospital ,a tertiary health care centre of Nepal. Head and Neck cancers are the sixth most common cancer in the world. Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023.The main aim of the study was to know about the common cancers of head and neck region and their distribution according to the site. Also to know the stage of the presentation with treatment modalities in the tertiary health care centre of Nepal.
Detailed description
This is a retrospective study to know the prevalence of Head and Neck Cancer at the department of ENT- Head and Neck Surgery of Shree Birendra Hospital ,a tertiary health care centre of Nepal .Head and neck cancers are malignant neoplasms that develops in oral cavity, nasal cavities, paranasal sinuses,nasopharynx, oropharynx, hypopharynx, ear, scalp, salivary gland and neck,Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023. Data considered of demographic details of age, sex, diagnosis, subsite specific Head and Neck Cancers, treatment modality and histopathology. The data was analyzed using Stastical Package for Social Sciences (SPSS) version 22. Pearson's chi-square test was applied and p value <0.05 was considered statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 17 to 84 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Study population was selected from the tertiary care centre of Nepal.
Key inclusion criteria (1 listed)
- All histologically proven cases of head and neck region.
Key exclusion criteria (1 listed)
- Patient's record with incomplete data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Age - wise Distribution of Head and Neck Cancers (HNCs)
Time frame: 1 year
Age - wise Distribution of Head and Neck Cancer
: Distribution of HNCs according to subsite
Time frame: 1 year
Distribution of Head and Neck Cancers according to the subsite
Histopathology of HNCs
Time frame: 1 year
Histopathology of Head and Neck Cancer
Tumor, Nodes, Metastasis (TNM) staging of HNC
Time frame: 1 year
Staging at presentation of Head and Neck Cancer
Treatment provided to HNC patients
Time frame: 1 year
Treatment Modalities of Head and Neck Cancer
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Background: PubMed 16831082Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8. doi: 10.1586/14737140.6.7.1111.
- Individual participant dataSharing planned: No. There is no plan to share the individual participant data to protect the privacy of the participants.
Related trials for Head and Neck Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Reeba Karki, MS principal investigator
Shree Birendra Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Head and Neck Cancer, run by Tribhuvan University, Nepal at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Age - wise Distribution of Head and Neck Cancers (HNCs) (time frame: 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06152055, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.